ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1195

Activation of the nlrp3 Inflammasome By an Endogenous TLR2 Ligand in Rheumatoid Arthritis

Mary Connolly, Trudy McGarry, Monika Biniecka, Douglas J. Veale and Ursula Fearon, Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cytokines, inflammasome activation, Inflammation, rheumatoid arthritis (RA) and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Signaling Mechanisms

Session Type: Abstract Submissions (ACR)

Background/Purpose: The inflammasome is a large multiprotein complex which plays a key role in innate immunity by mediating the production of pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18.  The most characterised inflammasome is nlrp3, activation of which results in numerous biological effects associated with infection, inflammation and autoimmune processes. While the inflammasome has traditionally been thought to regulate infection and inflammation, impaired mitochondrial metabolism may mediate this process. In this study we examined the interplay between the inflammasome and mitochondrial function following TLR2 activation.

Methods: Mitochondrial mutagenesis was assessed by Random Mutation Capture Assay. Reactive oxygen species were measured by cellular detection assay.  Primary RASFC and whole ex vivo synovial tissue were stimulated with a TLR2 agonist, PAMCSK, in the presence of absence of N-Acetyl Cysteine (NAC). IL-1β and IL-18 expression was examined by PCR.  Nlrp3 expression was assessed by real-time PCR and western blot. To establish whether A-SAA activates TLR, human embryonic kidney (HEK) -TLR2 or -TLR4 cells were cultured in the presence of A-SAA and NFκB luciferase activity was examined.  In parallel, the effect of A-SAA on RASFC function was examined in the presence of a specific neutralising anti-TLR2 mAb (1μg/ml) and matched IgG isotype control Ab (1μg/ml).  RASFC  proliferation,  adhesion,  chemokine expression,  migration and invasion were assessed by proliferation assays, flow cytometry, Taqman PCR, ELISA, wound repair and transwell assays. 

Results:  PAM3CYSK4 significantly induced mitochondrial mutagenesis and reactive oxygen species in RA synovial explants cultures and fibroblasts (p<0.05). TLR2 activation increased transcript levels of inflammasome and pro-inflammatory mediators including IL-1, IL-18 and nlrp3. Furthermore, activation of TLR2 induced IL-6, IL-8, IL-1, IL-18 at a protein level, effects which were significantly inhibited in presence of NAC, an ROS inhibitor (all p<0.05). Additionally, we demonstrated that A-SAA is an endogenous TLR2 ligand since it induced TLR2 mediated NF-κB lucifearse activity (p<0.05), with no effect observed for NFκB in HEK-TLR4 cells. A-SAA significantly induced NLRP3 mRNA and protein expression. In parallel, A-SAA induced RASFC proliferation, ICAM-1 expression, invasion and migration, all of which were significantly inhibited in the presence of anti-TLR2 (all p<0.05), further confirming its role as an endogenous TLR2 ligand.

Conclusion: TLR2 induces mitochondrial dysfunction which plays a key role in the regulation of downstream inflammasome activation. TLR2-induced pro-inflammatory effects in RA may be mediated by endogenous secretion of A-SAA from the synovium at the site of inflammation.


Disclosure:

M. Connolly,
None;

T. McGarry,
None;

M. Biniecka,
None;

D. J. Veale,

Abbvie,

2,

MSD,

2,

Pfizer Inc,

2,

Roche ,

2,

Pfizer ,

5,

Roche ,

5,

Abbott,

8,

MSD,

8,

Pfizer,

8,

Roche ,

8;

U. Fearon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activation-of-the-nlrp3-inflammasome-by-an-endogenous-tlr2-ligand-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology